Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different bindingaffinities to androgen receptors. Factors other than bindingaffinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its bindingaffinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as bindingaffinity, time of inhibition, safety data and cost.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.